CD274 and neoplasm: Tumor cells have been reported to evade immune surveillance by immune checkpoint signaling activation, for example, through PD-1/PD-L1 activation, and ROS/RNS removal improves the therapeutic effects of the PD-1/PD-L1 checkpoint blockade [62].